Enhanced downregulation of the phosphorylation-induced activation of Akt, PTEN, and PDK1was also observed in combination with a PI3K inhibitor, showing a synergistic anti-tumor efficacy compared to paclitaxel alone in paclitaxel resistance cells (Figure 3). This evidence concerns the gene AKT1 and neoplasm.